CN103665088A - Antineoplastic compound extracted from gamboge, and preparation method and application thereof - Google Patents
Antineoplastic compound extracted from gamboge, and preparation method and application thereof Download PDFInfo
- Publication number
- CN103665088A CN103665088A CN201310654336.5A CN201310654336A CN103665088A CN 103665088 A CN103665088 A CN 103665088A CN 201310654336 A CN201310654336 A CN 201310654336A CN 103665088 A CN103665088 A CN 103665088A
- Authority
- CN
- China
- Prior art keywords
- compound
- gradient elution
- chloroform
- methanol
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to an antineoplastic compound extracted from gamboge, and a preparation method and application thereof. The preparation method of the compound comprises: (1) selecting gamboge medicinal material, performing extraction with ethyl acetate, performing silica gel column chromatography separation on the extract product, performing gradient eluting with petroleum ether-ethyl acetate and obtaining 11 compositions A-K; (2) discarding grease composition and gambogic acid composition, repeatedly analyzing by HPLC-PDA-MS and obtaining the important composition I; (3) performing silica gel column chromatography separation on the composition I, performing gradient eluting with chloroform-methanol and obtaining an fraction I-2; (4) performing silica gel column chromatography separation on I-2, performing gradient eluting with chloroform-methanol and obtaining an sub-fraction I-2A; and (5) performing reversed-phase RP-18 separation on I-2A and acetonitrile-water gradient eluting to obtain the composition provided by the invention. The compound provided by the invention is applicable to tumor treatment.
Description
Technical field
The present invention relates to medical technical field, particularly a kind ofly from Chinese medicinal materials gamboge, extract separated compound, prepare the method for described compound, the medical composition that comprises described compound, and use described compound to prepare the purposes of antitumor drug.
Background technology
Gamboge is that the trunk of Garcinia maingayii gamboge (Garcinia hanburyi Hook f.) is hurt the colloidal resin of rear outflow, has another name called extra large rattan, beautiful Huang, month Huang, cured Huang etc.Originate in South East Asia, there is introducing culture China some areas as Yunnan, Guangxi, Guangdong and other places.
The gamboge beginning is loaded in < < Haiyao Bencao, Oversea Materia Medica > >, it is cold in nature, taste is sour, puckery, pungent, poisonous, there is the effect of broken blood dissipating bind, removing toxic substances, hemostasis, desinsection, the traditional Chinese medical science is used for controlling swollen ulcer drug, stubborn dermatitis is disliked sore, bleeding due to trauma, noma decayed tooth, burn.
At present, reported from gamboge, be divided into from identified more than 20 compounds, be mostly xanthone (xanthone) compounds containing bridged ring, i.e. gambogic acid, Mo Lilin class, morellin class, and gamboge aldehyde, Betulinic acid etc. multiple compounds.
Modern pharmacology research shows, Resina garciniae extract has the anti-microbial activity of wide spectrum, and streptococcus aureus, Pseudomonas aeruginosa etc. is had to stronger bacteriostatic action.And pharmacological evaluation and clinical experience prove, it has antitumor action, can effectively suppress tumor proliferation, and kinds of tumors is had to significant curative effect.
Contriver extracts and obtains having bioactive the compounds of this invention from gamboge, compares have more superior anti-tumor activity with morellic acid.
Summary of the invention
The invention provides a kind of from gamboge, extract separated have bioactive formula (1) compound the purposes that the preparation method of this compound is provided and has prepared medicine for treating tumor thing.
Formula (1) compound has following formula:
The present invention also provides the preparation method of this formula (1) compound, and concrete steps are:
(1) get gamboge medicinal material and extract by ethyl acetate, extract is separated through silica gel column chromatography, and petroleum ether-ethyl acetate gradient elution, obtains 11 component A～K;
(2) discard oil component and morellic acid component, through HPLC-PDA-MS, analyze, obtain emphasis component I;
(3) component I is separated through silica gel column chromatography again, chloroform-methanol gradient elution, and every 30ml collects a flow point, merges the 6th part to the 10th part elutriant, and flow velocity is 2mL/min, obtains flow point I-2;
(4) get I-2 through silica gel chromatography separation, chloroform-methanol gradient elution, every 8ml collects a flow point, merges the 2nd part to the 6th part elutriant, and flow velocity is 2mL/min, obtains Arius and divides I-2A;
(5) I-2A, through anti-phase RP-18 separation, acetonitrile-water gradient elution, obtains formula (1) compound.
Preferably, step (1) PetroChina Company Limited. ether-ethyl acetate by volume 50～0: 1 ratio carry out gradient elution;
Preferred, petroleum ether-ethyl acetate is divided into six gradients and carries out wash-out, be respectively 50: 1, and 10: 1,5: 1,2: 1,1: 1,0: 1.
Preferably, in step (3) chloroform-methanol by volume 50～10: 1 ratio carry out gradient elution;
Preferably, in step (4) chloroform-methanol by volume 30～10: 1 ratio carry out gradient elution;
Preferred, chloroform-methanol is divided into three gradients and carries out wash-out, is respectively 30: 1,20: 1,10: 1.
Preferably, in step (5) acetonitrile-water by volume 50～80: 50～20 ratio carry out gradient elution;
Preferred, acetonitrile-water is divided into four gradients and carries out wash-out, be respectively 50: 50, and 60: 40,70: 30,80: 20.
Contriver by physico-chemical property and the Modern spectroscopy section of learning to do (
1h-NMR (Fig. 2),
13c-NMR (Fig. 3), HR-ESI-MS,
1h-
1h COSY and HSQC) the separated compound obtaining has been carried out to Structural Identification, be confirmed that it is structure suc as formula the compound shown in (1).
In one aspect, formula of the present invention (1) compound can be used for the treatment of tumor disease.Contriver finds that the compounds of this invention has the inhibition activity of wide spectrum to tumour cell.Described tumor disease comprises the group that is selected from following composition: nasopharyngeal carcinoma, mammary cancer, mice sarcoma cell and carcinoma of the pancreas.
Another aspect, the present invention also provides the pharmaceutical composition for the treatment of tumor disease, it comprises formula (1) compound for the treatment of significant quantity, and at least one is selected from following pharmaceutically acceptable non-active ingredient: pharmaceutically acceptable thinner, pharmaceutically acceptable vehicle and pharmaceutically acceptable supporting agent.
Accompanying drawing explanation
Fig. 1 is formula (1) structural formula of compound;
Fig. 2 is formula (1) compound
1h-NMR spectrum;
Fig. 3 is formula (1) compound
13c-NMR spectrum.
Embodiment
compound
Formula (1) compound has following structure:
medical composition/composite
Applicable dispensing path includes, but is not limited to per os, intravenously, rectum, aerosol, non-through intestines, eye, lung, through mucous membrane, through skin, vagina, ear, intranasal, intramuscular injection, subcutaneous injection and topical administration.In addition, only for instance, non-ly through intestines transmission, comprise intramuscular, subcutaneous, intravenously, intramedullary injection, and in sheath, directly in indoor, intraperitoneal, lymph and nasal injection.
In certain embodiments, compound as herein described is with part but not general mode administration.In other embodiments, compound as herein described provides to discharge fast composite form, prolongation release composite form or the middle composite form that discharges.In other embodiments, compound as herein described is local administration.
In certain embodiments, compound as herein described is through being allocated as medical composition.In a particular embodiment, medical composition in the usual way, with one or more physiologically acceptable supporting agents, allocate, described physiologically acceptable supporting agent comprises vehicle and auxiliary agent, and it contributes to active compound to be processed as the preparation that can be used for pharmacy.Suitably composite depends on selected dosing way.
Medical composition refers to the mixture of formula (1) compound and other chemical composition, and described chemical composition is as being supporting agent, stablizer, thinner, dispersion agent, suspension agent, thickening material and/or vehicle.In certain embodiments, medical composition contributes to Mammals administration compound.
In certain embodiments, compound as herein described is through allocating for oral administration.Compound as herein described is allocated with oral dosage form, and only for instance, described oral dosage form comprises tablet, pulvis, pill, sugar-coat ingot, capsule, liquid, gel, syrup, elixir, slurries, suspension and analogue thereof.
In certain embodiments, described medical composition is tablet, capsule, powder ampoule agent for injection, injection, pill and slow releasing tablet.
In one embodiment, formula (1) compound is allocated in the aqueous solution.In a particular embodiment, only for instance, the aqueous solution is selected from physiological compatibility damping fluid, as Han Shi liquid (Hank ' s solution), ringer's solution (Ringer ' s solution) or normal saline buffer solution.
In other embodiments, formula (1) compound is used for offeing medicine through mucous membrane through allotment.In a particular embodiment, through mucous membrane composite, comprise the permeate agent that is suitable for wanting permeability barrier.
At compound as herein described, through allotment, be used for other non-other embodiment through enteral administration, suitably composite comprises water-based or non-aqueous solution.
In certain embodiments; by mixing one or more solid excipients and one or more compounds as herein described, optionally grind gained mixture and add to be applicable to where necessary auxiliary agent post-treatment granular mixture and obtain to obtain tablet or pill the pharmaceutical preparation using for per os.Specifically, suitable vehicle is weighting agent, as sugar, comprises lactose, sucrose, N.F,USP MANNITOL or sorbyl alcohol; Cellulose preparation, as W-Gum, wheat starch, rice starch, yam starch, gelatin, tragacanth, methylcellulose gum, Microcrystalline Cellulose, Vltra tears, Xylo-Mucine; Or other material, as polyvinylpyrrolidone (PVP or polyvidone) or calcium phosphate.In a particular embodiment, optionally add disintegrating agent.Only for instance, disintegrating agent comprises croscarmellose sodium, polyethylene pyrroles a heatable brick bed ketone, agar or Lalgine or its salt, as sodium alginate.
Oral dosage form also comprises the cooperation insertion capsule of being made by gelatin, and the soft seal capsule of being made by gelatin and softening agent (as glycerine or sorbyl alcohol).In a particular embodiment, coordinate and insert the mixture that capsule contains activeconstituents and one or more weighting agents.Only for instance, weighting agent comprises lactose, as tackiness agents such as starch and/or as lubricants such as talcum or Magnesium Stearates, and the optional stablizer using.In other embodiments, soft capsule contains one or more dissolvings or is suspended in the active compound in suitable liquid.Only for instance, suitably liquid comprises one or more fatty oils, liquid paraffin or liquid polyethylene glycol.In addition, optionally add stablizer.
In other embodiments, formula (1) compound is local administration.Composition that can local administration comprises solution, suspension, lotion, gel, paste, swab, balm, newborn frost or ointment.
In other embodiments, formula (1) compound is through allocating for inhalation dosing.The various forms that is suitable for inhalation dosing includes, but is not limited to aerosol, spraying or pulvis.
In order to make those skilled in the art understand better technical scheme of the present invention, below in conjunction with specific embodiment, the present invention is described in further detail.Provide described example only for purpose of explanation, and wish does not limit the scope of claims provided herein.
The preparation method of embodiment 1 formula of the present invention (1) compound
(1) by ethyl acetate, extract gamboge medicinal material (weight ratio of ethyl acetate and gamboge is 15: 1), extract is separated through silica gel column chromatography, and petroleum ether-ethyl acetate (50: 1,10: 1,5: 1,2: 1,1: 1,0: 1) six gradient elutions, flow velocity is 2mL/min, every 30ml collects once, and every 7 parts of merging, obtain 11 component A～K;
(2) discard after oil component A and B and morellic acid component D and E, then analyze through HPLC-PDA-MS, obtain emphasis component I;
(3) component I is separated through silica gel column chromatography again, chloroform-methanol (50: 1～10: 1) gradient elution, and every 30ml collects a flow point, merges the 6th part to the 10th part, and flow velocity is 2mL/min, obtains flow point I-2;
(4) get I-2 through separated through silica gel chromatography, and chloroform-methanol (30: 1,20: 1,10: 1) wash-out, every 8ml collects successively, merges the 2nd part to the 6th part, and flow velocity is 2mL/min, obtains Arius and divides I-2A;
(5) 1-2A is separated through anti-phase RP-18, and acetonitrile-water (50～80: 50～20) gradient elution,, obtain formula of the present invention (1) compound.
The Structural Identification of embodiment 2 formula of the present invention (1) compound
This compound is white amorphous powder,
(c0.21, MeOH);
1h and
13cNMR data are in Table 1; IR (KBr) v
max3429,2947,1720,1695,1642,1365,1252,1142,1080,1047cm
-1; HR-TOF-MS shows quasi-molecular ion peak m/z711.4090[M+Na]
+(cald for C
39h
60o
10na, 711.4084).
The nuclear magnetic data of table 1 formula (1) compound (
1h (500MHz, C
5d
5n),
13c (100MHz, C
5d
5n) NMR)
Embodiment 3
The restraining effect of formula (1) compound to people's lung cancer transplanted tumor
1. materials and methods
1.1 tested material
Formula (1) compound: 10mg/ml, purity 98.5%, lot number 20100121, is prepared by Shanghai Pharmaceutical Inst., Chinese Academy of Sciences.
Vinorelbine tartrate injection liquid (Gai Nuo): Jiangsu Haosen Pharmaceutical Co., Ltd, lot number 100301.
Physiological saline: Shandong Lukang Cisen Pharmaceutical Co., Ltd, lot number 1004234202.
Morellic acid: 10mg/ml, purity 98% (detecting through HPLC), lot number 20100819, is prepared by Kangyuan Pharmaceutical Co., Ltd., Jiangsu Prov.
1.2 transplanted tumor
People's lung cancer NCI-H460 Nude Mice, is inoculated in nude mouse by people's lung cancer NCI-H460 cell strain subcutaneous and set up.Cell inoculum size is 3 * 10
6, inoculation is used after forming and passing for 3 generations again in nude mouse body after transplanted tumor.
1.3 animal
Female BALB/c nude mouse, age in days 35-40 days, body weight 18-22g, is provided by Nanjing Military Command hospital general experimentation on animals section.12 of the negative control groups of every treated animal number, 6 of administration groups.
1.4 test method
The tumor tissue of getting growth animated period cuts into 1.5mm
3left and right, under aseptic condition, is inoculated in nude mouse right side armpit subcutaneous.Vernier caliper measurement transplanted tumor diameter for Nude Mice, treats tumor growth to 100～300mm
3after by animal random packet.Use the method for measuring knurl footpath, dynamically observe the antineoplastic effect of tested medicine.The measurement number of times of diameter of tumor is 3 times weekly, and each measurement also needs to claim mouse heavy simultaneously.Formula (1) compound intravenously administrable, dosage divides and is 12mg/kg, 6mg/kg, 3mg/kg, gives three times weekly.Lid promise intravenously administrable 10mg/kg, gives twice weekly, each 0.2ml, and negative control group is given equivalent physiological saline simultaneously.
1.5 detect index and method of calculation
(1) gross tumor volume (tumor volume, TV), calculation formula is:
(2) relative tumour volume (relative tumor volume, RTV), calculation formula is:
RTV＝TV
t/TV
0
TV wherein
0(d during for minute cage administration
0) gross tumor volume, TV
tgross tumor volume when measuring each time.
(3) relative tumor proliferation rate T/C (%), calculation formula is:
T/C(％)＝T
RTv/C
RTV×100
T
rTV: treatment group RTV; C
rTV: negative control group RTV.
Test-results is usingd the evaluation index of relative tumor proliferation rate T/C (%) as anti-tumor activity.
1.6 statistical method
Experimental data represents with mean value and standard deviation, statistical method employing t-check.
2. result
Formula (1) compound the results are shown in Table 2 to the experimental treatment of people's lung cancer NCI-H460.
Formula (1) compound high dose group intravenously administrable has good growth-inhibiting effect to people's lung cancer NCI-H460 mice-transplanted tumor, and preferably T/C (%) is 62.33;
Middle dosage group intravenously administrable 6mg/kg has certain growth-inhibiting effect to people's lung cancer NCI-H460 Nude Mice, and preferably T/C (%) is 69.91;
Low dose group intravenously administrable 3mg/kg has certain growth-inhibiting effect to people's lung cancer NCI-H460 mice-transplanted tumor, and preferably T/C (%) is respectively 70.05;
Lid promise intravenously administrable 10mg/kg has certain growth-inhibiting effect to people's lung cancer NCI-H460 Nude Mice, and preferably T/C (%) is 56.69;
Morellic acid intravenously administrable 12mg/kg has certain growth-inhibiting effect to people's lung cancer NCI-H460 Nude Mice, and preferably T/C (%) is 70.55.
The experimental therapy of people's lung cancer NCI-H460 Nude Mice during table 2 formula (1) compound
D1 divides the RTV of cage administration time P administration group and RTV contrast *: the P < 0.05**:P < 0.01 of blank group
The extracorporeal anti-tumor function of embodiment 4 the compounds of this invention
1. experiment material
1.1 cell strain
CNE: human nasopharyngeal carcinoma cell line, purchased from Chinese Academy of Sciences's cell bank;
Bcap-37: human breast cancer cell strain, purchased from Chinese Academy of Sciences's cell bank;
S180: mice sarcoma cell strain, purchased from Chinese Academy of Sciences's cell bank;
Bxpc-3: human pancreas cancer cell strain, purchased from Chinese Academy of Sciences's cell bank;
MCF-7: human breast cancer cell strain, purchased from Chinese Academy of Sciences's cell bank.
1.2 tested material and reagent
Formula (1) compound: purity 98.5%, lot number 20100121, is prepared by Shanghai Pharmaceutical Inst., Chinese Academy of Sciences;
0.25% trypsinase-EDTA: U.S. GIBCO company;
MTT solution: purchased from Si Baihui bio tech ltd, Beijing;
PBS damping fluid: Ji Nuo biological medicine technology company limited;
Dimethyl sulfoxide (DMSO) (DMSO): analytical pure.
1.3 experimental technique
1.3.1 cell in vitro is cultivated
The cell Soviet Union of often restoring to norm is placed in incubator at 37 ℃, 5%CO
2and cultivate under saturated humidity condition, until Growth of Cells, during to exponential phase of growth, with 0.25% trypsinase-DTA digestion method, go down to posterity.Absorb old nutrient solution in bottle, with PBS, wash away residual nutrient solution, in bottle, add appropriate Digestive system (0.25% trypsinase-EDTA) again, make Digestive system submergence all cells surface, put and in 37 ℃ of incubators, hatch (time is depending on different cells), put under microscope and observe, after finding that kytoplasm retraction, intercellular substance increase, add immediately the complete culture solution containing serum to stop digestion, centrifugal (1000rpm, 5min), remove supernatant liquor, with counting after nutrient solution re-suspended cell, with cell count 3 * 10
5～5 * 10
5cells/mL is seeded in new culturing bottle, is placed in incubator and cultivates with above-mentioned culture condition, and 2～3d goes down to posterity once.
1.3.2MTT method detects
Growth of Cells is during to exponential phase of growth, with 0.25% trypsinase-DTA digestion, centrifugal (1000rpm, 5min), it is 2 * 10 that cell precipitation is adjusted cell count with perfect medium
4～3 * 10
4cells/mL, 96 holes are cultivated the every hole of version and are inoculated 190 μ L, at 37 ℃, 5%CO
2and cultivate under saturated humidity condition, after 24h, add formula (1) compound, making cumulative volume is 200 μ L, establishes 6 multiple holes, control wells adds PBS solution, continues to cultivate 48h, then adds the MTT that 20 μ L concentration are 5mg/mL, is placed in CO
237 ℃ of incubators are hatched, and discard nutrient solution after 4h, and every hole adds 150 μ LDMSO, and vibration 10min, puts in enzyme micro-plate reader and detect, and measures the OD value in each hole, calculating inhibiting rate.The IC of formula (1) compound to subject cell strain
50with SPSS11.5 software, by probit's weighted regression method, calculate.
Inhibiting rate calculation formula:
2. experimental result
Experimental result shows (as table 3), and formula (1) compound all has restraining effect to each tested tumour cell, and wherein Mouse sarcoma S180 cells strain is the highest to the susceptibility of medicine.
The IC of table 3 formula (1) compound to each subject cell strain
50 
The preparation of embodiment 5 tablets
Working method according to conventional tablet, more than mixes, and wet granulation finally adds Magnesium Stearate to mix and is pressed into tablet, and totally 50, every 500mg.
The preparation of embodiment 6 capsules
Working method according to conventional capsule, more than mixes, wet granulation, filling one-tenth capsule, totally 90, every 300mg.
The preparation of embodiment 7 pills
Formula (1) compound 10.0g
Polyethylene glycol 6000 25.0g
Formula (1) compound was pulverized to 100 mesh sieves, evenly added in the polyethylene glycol 6000 matrix of melting, stirred 30 minutes to even, take dimethyl silicone oil 100 as refrigerant, and 15-4 ℃ of gradient is cooling, and dripping becomes ball, the agent of centrifugal removal surface cool, obtains dripping pill 1000 balls.
The preparation of embodiment 8 powder ampoule agent for injection
Formula (1) compound 1.0g
Hydrochloric acid is appropriate
N.F,USP MANNITOL 50.0g
According to the operation of conventional freeze-dried powder, carry out, formula (1) compound adds 800ml water for injection and dissolves, and adds N.F,USP MANNITOL, is settled to 1000ml, regulates pH value between 5.0-6.5, Sterile Filtration, lyophilize and get final product.
The preparation of embodiment 9 injections
Formula (1) compound is dissolved in to dehydrated alcohol, adds 20% Soxylat A 25-7 Viscotrol C to mix, reduction vaporization is removed ethanol, adds appropriate water for injection to be mixed into clear solution, through filtering with microporous membrane, and coating-dividing sealing, flowing steam sterilization and get final product.
The preparation of embodiment 10 slow releasing tablets
Formula (1) compound and polyvidone are dissolved in a small amount of ethanol, reduction vaporization ethanol, gained solid is crossed 100 mesh sieves; Above-mentioned solid and lactose, hypromellose are crossed to 60 mesh sieves and mix, add 3% HPMC (E5) aqueous solution softwood processed in right amount, cross 20 mesh sieves and granulate, forced air drying.Dry particle is crossed the whole grain of 20 mesh sieves, adds the talcum powder of recipe quantity, mixes compressing tablet and get final product.
The above is only the preferred embodiment of the present invention; it should be pointed out that for those skilled in the art, under the premise without departing from the principles of the invention; can also make some improvements and modifications, these improvements and modifications also should be considered as protection scope of the present invention.
Claims (14)
1. a formula (1) compound:
。
2. a medical composition, it comprises the compound according to claim 1 for the treatment of significant quantity, and at least one is selected from following pharmaceutically acceptable non-active ingredient: pharmaceutically acceptable thinner, pharmaceutically acceptable vehicle and pharmaceutically acceptable supporting agent.
3. medical composition according to claim 2, wherein said medical composition is tablet, capsule, powder ampoule agent for injection, injection, pill and slow releasing tablet.
4. according to the purposes of the compound described in claims 1 to 3 or medical composition, it is for the preparation of the medicine that is used for the treatment of tumor disease.
5. purposes according to claim 4, described tumor disease is selected from the group of following composition: nasopharyngeal carcinoma, mammary cancer, mice sarcoma cell and carcinoma of the pancreas.
6. purposes according to claim 5, described tumor disease is mice sarcoma cell.
7. a method of preparing compound according to claim 1, it comprises the following steps:
(1) get gamboge medicinal material and extract by ethyl acetate, extract is separated through silica gel column chromatography, and petroleum ether-ethyl acetate gradient elution, obtains 11 component A～K;
(2) discard oil component and morellic acid component, through HPLC-PDA-MS, analyze, obtain emphasis component I;
(3) component I is separated through silica gel column chromatography again, chloroform-methanol gradient elution, and every 30ml collects a flow point, merges the 6th part to the 10th part elutriant, and flow velocity is 2mL/min, obtains flow point I-2;
(4) get I-2 through silica gel chromatography separation, chloroform-methanol gradient elution, every 8ml collects a flow point, merges the 2nd part to the 6th part elutriant, and flow velocity is 2mL/min, obtains Arius and divides I-2A;
(5) I-2A, through anti-phase RP-18 separation, acetonitrile-water gradient elution, obtains formula (1) compound.
8. method according to claim 7, wherein said step (1) PetroChina Company Limited. ether-ethyl acetate by volume 50～0: 1 ratio is carried out gradient elution.
9. method according to claim 8, wherein said petroleum ether-ethyl acetate is divided into six gradients and carries out wash-out, is respectively 50: 1,10: 1,5: 1,2: 1,1: 1,0: 1.
10. method according to claim 7, in wherein said step (3) chloroform-methanol by volume 50～10: 1 ratio carry out gradient elution.
11. methods according to claim 7, the middle chloroform-methanol of wherein said step (4) by volume 30～10: 1 ratio carries out gradient elution.
12. methods as claimed in claim 11, wherein chloroform-methanol is divided into three gradients and carries out wash-out, is respectively 30: 1,20: 1,10: 1.
13. methods as claimed in claim 7, the middle acetonitrile-water of wherein said step (5) by volume 50～80: 50～20 ratio carries out gradient elution.
14. methods according to claim 13, wherein said acetonitrile-water is divided into four gradients and carries out wash-out, is respectively 50: 50,60: 40,70: 30,80: 20.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310654336.5A CN103665088B (en) | 2013-11-28 | 2013-11-28 | Antitumoral compounds extracted from Resina garciniae and preparation method thereof and purposes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310654336.5A CN103665088B (en) | 2013-11-28 | 2013-11-28 | Antitumoral compounds extracted from Resina garciniae and preparation method thereof and purposes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103665088A true CN103665088A (en) | 2014-03-26 |
| CN103665088B CN103665088B (en) | 2016-07-13 |
Family
ID=50303949
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310654336.5A Active CN103665088B (en) | 2013-11-28 | 2013-11-28 | Antitumoral compounds extracted from Resina garciniae and preparation method thereof and purposes |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103665088B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101607978A (en) * | 2008-06-20 | 2009-12-23 | 秦继红 | Two new compounds, its preparation method and pharmaceutical uses in the gamboge |
-
2013
- 2013-11-28 CN CN201310654336.5A patent/CN103665088B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101607978A (en) * | 2008-06-20 | 2009-12-23 | 秦继红 | Two new compounds, its preparation method and pharmaceutical uses in the gamboge |
Non-Patent Citations (8)
| Title |
|---|
| THOISON O ET AL.: "Insect antifeedant compounds from Nothofagus dombeyi and N. pumilio", 《PHYTOCHEMISTRY》 * |
| WANG LL ET AL.: "Two novel triterpenoids with antiproliferative and apoptotic activities in human leukemia cells isolated from the resin of Garcinia hanburyi", 《PLANTA MED》 * |
| 华会明等.: "四种药用植物抗肿瘤活性成分的研究", 《中国化学会第八届天然有机化学学术研讨会论文集》 * |
| 张俊艳等.: "藤黄属植物的化学成分和药理作用研究进展", 《现代药物与临床》 * |
| 李占林等.: "藤黄抗肿瘤活性成分的研究", 《第七届全国天然有机化学学术研讨会论文集》 * |
| 杨光忠等.: "藤黄化学成分的研究", 《中南民族大学学报（自然科学版）》 * |
| 王丽莉: "藤黄和双籽藤黄化学成分及抗肿瘤活性研究", 《中国博士学位论文全文数据库（医药卫生科技辑）》 * |
| 贾明美等.: "藤黄化学成分的研究", 《化学学报》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103665088B (en) | 2016-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101890030B (en) | Composite capable of preventing bacteria, viruses, oxidation and pigment deposition | |
| CN108926584A (en) | The antimicrobial purposes of chimonanthea extract | |
| CN103664986B (en) | Antineoplastic compound extracted from gamboge and preparation method thereof and purposes | |
| CN103664984A (en) | Antineoplastic compound extracted from gamboge, and preparation method and application thereof | |
| CN104940781A (en) | Traditional Tibetan medicine composition for treating nervous system diseases and preparation method thereof | |
| CN103694248A (en) | Antitumor compound extracted from guttifer, and preparation method and application thereof | |
| CN103664997A (en) | Antitumor compound extracted from gamboge and preparation method and application thereof | |
| CN1919339B (en) | Cucurbitacin nano preparation comprising protein, preparation method and use thereof | |
| CN103665088A (en) | Antineoplastic compound extracted from gamboge, and preparation method and application thereof | |
| CN103665089A (en) | Antineoplastic compound extracted from gamboge, and preparation method and application thereof | |
| CN103664983A (en) | Antineoplastic compound extracted from gamboge, and preparation method and application thereof | |
| CN103724313A (en) | Antineoplastic compound extracted from cambogia and preparation method and application of antineoplastic compound | |
| CN103694303A (en) | Antitumor compound extracted from guttifer, and preparation method and application thereof | |
| CN103664979A (en) | Antineoplastic compound extracted from gamboge, and preparation method and application thereof | |
| CN112402413B (en) | Application of lindley eupatorium herb sesquiterpene lactone B in preparation of anti-liver cancer medicine and anti-liver cancer medicine | |
| CN1686490A (en) | Chinese medicinal composition, its preparation method and quality control method | |
| CN109364148A (en) | A kind of FUKE QIANJIN PIAN and preparation method thereof | |
| CN105769776B (en) | A kind of freeze-dried composition for treating non-Hodgkin lymphoma and preparation method thereof | |
| CN109470788A (en) | A kind of method of quality control of FUKE QIANJIN PIAN | |
| CN104940177B (en) | Medical application of vine flavone F | |
| CN102961380A (en) | Pharmaceutical composition for treating acute lung injury | |
| CN108926583A (en) | The purposes of Zhejiang wintersweet anti-microbial infection | |
| CN1241571C (en) | Use of centella total glycoside in manufacture of medicine | |
| CN101161652B (en) | Quinolizine derivatives having antibacterial activity | |
| CN109553565B (en) | Two new alkaloids, preparation method thereof and application thereof in preparation of MRSA-resistant antibacterial agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |